1-（4-苯氧基苄基）5-氨基尿嘧啶衍生物及其类似物——新型人腺病毒复制抑制剂

Nikitenko N A, Gureeva E S, Ozerov A A, Tukhvatulin A I, Izhaeva F M, Prassolov V S, Deryabin P G, Novikov M S, Logunov D Y

N.F. Gamaleya Federal National Research Center for Epidemiology and Microbiology, Gamaleya Str. 18, Moscow, 123098, Russia.

Volgograd State Medical University, Pavshih Bortsov Sq. 1,Volgograd, 400131, Russia.

Acta Naturae. 2018 Apr-Jun;10(2):58-64.

Adenovirus infections are characterized by widespread distribution. The lack of causal therapy, which is effective in treating this group of diseases, explains the need for new therapeutic drugs. Notably, anti-adenoviral activity of [4-(phenoxy)benzyl]-5-(phenylamino)-6-azauracil, 1-[4-(phenoxy)benzyl]-5-(morpholino) uracil, 1-[4-(4-chlorophenoxy)benzyl]-5-(morpholino) uracil, and 1-[4-(4-fluorophenoxy)-benzyl]-5-(morpholino) uracil was observed.

腺病毒感染的特点是分布广泛。由于缺乏对这类疾病有效的病因治疗方法，因此需要新的治疗药物。值得注意的是，观察到了[4-(苯氧基)苄基]-5-(苯氨基)-6-氮杂尿嘧啶、1-[4-(苯氧基)苄基]-5-(吗啉代)尿嘧啶、1-[4-(4-氯苯氧基)苄基]-5-(吗啉代)尿嘧啶和1-[4-(4-氟苯氧基)苄基]-5-(吗啉代)尿嘧啶的抗腺病毒活性。